A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy

Journal of the National Cancer Institute

Volumn 105, Issue 13, 2013, Pages 968-977

  Ahmed, Atique U ^a   Thaci, Bart ^a   Tobias, Alex L ^a   Auffinger, Brenda ^a   Zhang, Lingjiao ^a   Cheng, Yu ^a   Kim, Chung Kwon ^a   Yunis, Catherine ^a   Han, Yu ^a   Alexiades, Nikita G ^a   Fan, Xiaobing ^b   Aboody, Karen S ^b   Lesniak, MacIej S ^a,c  

^a Brain Tumor Center   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC ADENOVIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL MIGRATION; CELLULAR DISTRIBUTION; GLIOMA; GLIOMA CELL; HAZARD RATIO; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEURAL STEM CELLS; ONCOLYTIC VIROTHERAPY; STEM CELL TRANSPLANTATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880203393     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt141     Document Type: Article

References (29)

1. Conti L, Cattaneo E. Neural stem cell systems: physiological players or in vitro entities? Nat Rev Neurosci. 2010;11(3):176-187.
2. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial glio-mas. Proc Natl Acad Sci U S A. 2000;97(23):12846-12851.
3. Benedetti S, Pirola B, Pollo B, et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med. 2000;6(4):447-450.
4. Ahmed AU, Lesniak MS. Glioblastoma multiforme: can neural stem cells deliver the therapeutic payload and fulfill the clinical promise? Expert Rev Neurother. 2011;11(6):775-777.
5. Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, Pytel P. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin Oncol. 2011;38(2):243-253.
6. Alonso MM, Jiang H, Gomez-Manzano C, Fueyo J. Targeting brain tumor stem cells with oncolytic adenoviruses. Methods Mol Biol. 2012;797:111-125. doi:10.1007/978-1-61779-340-0-9.
7. Tyler MA, Ulasov I V, Sonabend AM, et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther. 2009;16(2):262-278.
8. Ahmed AU, Thaci B, Alexiades NG, et al. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol Ther. 2011;19(9):1714-1726.
9. Ahmed AU, Tyler MA, Thaci B, et al. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm. 2011;8(5):1559-1572.
10. Kanai R, Rabkin SD, Yip S, et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblas-toma stem cells. J Natl Cancer Inst. 2012;104(1):42-55.
11. Ulasov I V, Zhu ZB, Tyler MA, et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther. 2007;18(7):589-602.
12. Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res. 2006;12(7 Pt 1):2264-2271.
13. Thu MS, Najbauer J, Kendall SE, et al. Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PLoS One. 2009;4(9):e7218.
14. Ahmed AU, Alexiades NG, Lesniak MS. The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Curr Opin Mol Ther. 2010;12(5):546-552.
15. Ahmed AU, Ulasov I V, Mercer RW, Lesniak MS. Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors. Methods Mol Biol. 2012;797:97-109. doi:10.1007/978-1-61779-340-0-8.
16. Thaci B, Ahmed AU, Ulasov IV, et al. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther. 2012;19(6):431-442.
17. Kitange GJ, Carlson BL, Schroeder MA, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 2009;11(3):281-291.
18. Chahal M, Xu Y, Lesniak D, et al. MGMT modulates glioblastoma angio-genesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol. 2010;12(8):822-833.
19. Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther. 2010;18(2):243-250.
20. van Beusechem VW, van den Doel PB, Gerritsen WR. Conditionally repli-cative adenovirus expressing degradation-resistant p53 for enhanced onco-lysis of human cancer cells overexpressing murine double minute 2. Mol Cancer Ther. 2005;4(6):1013-1018.
21. Carney BJ, Shah K. Migration and fate of therapeutic stem cells in different brain disease models. Neuroscience. 2011;197:37-47. doi:10.1016/j.neuroscience.2011.08.063.
22. Das S, Basu A. Viral infection and neural stem/progenitor cell's fate: implications in brain development and neurological disorders. Neurochem Int. 2011;59(3):357-366.
23. Gage FH. Mammalian neural stem cells. Science. 2000;287(5457):1433-1438.
24. Miletic H, Fischer Y, Litwak S, et al. Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther. 2007;15(7):1373-1381.
25. Shah K, Bureau E, Kim DE, et al. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol. 2005;57(1):34-41.
26. Ubiali F, Nava S, Nessi V, et al. Allorecognition of human neural stem cells by peripheral blood lymphocytes despite low expression of MHC molecules: role of TGF-beta in modulating proliferation. Int Immunol. 2007;19(9):1063-1074.
27. Ring KL, Tong LM, Balestra ME, et al. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell. 2012;11(1):100-109.
28. Izpisua Belmonte JC, Ellis J, Hochedlinger K, Yamanaka S. Induced pluri-potent stem cells and reprogramming: seeing the science through the hype. Nat Rev Genet. 2009;10(12):878-883.
29. Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell. 2012;10(6):678-684.